Peter Diamandis

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross × Ben Lamm

Colossal is now worth over $10 billion with more than four spin-offs, while AI connects fragmented research and addresses 40–60% replication failure through standardized language.That data infrastructure may matter more than the model itself as comparative genomics spans thousands of genomes.Colossal has surpassed 300 edits at over 90% efficiency and is testing 1,000, with large-fragment DNA synthesis and a fully extrauterine mammalian birth within 24 months as catalysts amid ethical and regulatory constraints.

Peter Diamandis × Emad Mostaque × Cathie Wood × Nikhil Chandhok

Peter said a Tesla-SpaceX merger could be announced this year, and Cathie said ARK believes it will happen, combining rockets, broadband, AI, electric vehicles and energy around Musk’s Mars-directed compute strategy, though China remains a major obstacle.Nikhil Chandhok expects AI agents to outnumber humans next year, while Arc tests agent credit and stablecoin rails whose capacity must grow from tens of thousands to potentially millions of transactions per second.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross × Palmer Luckey

Anduril’s $2.2 million wildfire XPRIZE win, including $1 million from Lockheed, shows its autonomy workflow can transfer to emergencies where a 10-minute versus hour-long response requires different tools.Luckey’s specialized, verifiable systems and self-funded product model challenge a market where five companies once captured roughly 80% of major defense acquisition programs, while Anduril’s choice to use rather than build humanoids keeps platform scope and procurement scale in focus.

Peter Diamandis × Emad Mostaque

AI competition is shifting toward distribution: Meta Muse reached #1 in the App Store with 2.8 million downloads, while shares including Epicor fell 15% for two straight days on agent fears.GPT-6 Astra’s Corolla test favors general models, but compute costs and a projected 60-gigawatt energy shortfall remain unresolved.Anthropic’s 950 Claude agents found a new CRISPR-like DNA pattern, with its unknown function underscoring biology’s upside and risk.

Peter Diamandis × Salim Ismail × Dave Blundin × Dr. Alexander Wissner-Gross

AI’s next control layer may be machine-on-machine oversight, using readable activations and truthful real-world contexts.Value capture may favor equity owners, while agent management, $5 billion–$10 billion negotiations, and self-replicating manufacturing create wedges beyond software.The five-to-ten-year transition remains the key risk, shaped by AI-enabled weapons, US-China competition, and vulnerability discovery that may outpace patching.

Peter Diamandis × Dave Blundin × Alexander Wissner-Gross × Vlad Tenev

Robinhood Chain already handles well over $1 billion in daily DEX volume and roughly 200 tokenized U.S. stock tokens across 120-plus countries.That evidence strengthens Vlad Tenev’s tokenization thesis, while Bessant’s liability stance and Robinhood’s plumbing-not-alpha view define the regulatory, automation and competitive risks ahead.

Peter Diamandis × Salim Ismail × Dave Blundin × Dr. Alexander Wissner-Gross

Dario Amodei proposes slowing frontier releases through employee-level third-party evaluators, lab coordination, and international bioweapons cooperation, while Alex Wissner-Gross calls the campaign a possible “safety cartel.”Anthropic reports biological-weapons cases and says it can no longer confidently assure models remain below the dangerous threshold, strengthening the case for mutual API testing while leaving cartel-like coordination unresolved.

Peter Diamandis × Martine Rothblatt

United Therapeutics has four thymus shots on goal, including an FDA-approved xenothymus program and newly acquired Thymmune, making thymic replacement Rothblatt’s “most practical pathway” to LEV in the 2030s.Its xeno-kidney trial is mid-flight, facilities are slated for Rochester in August and Houston in October, and xeno-heart moved to Phase 3 after two patients survived 60 days without heart failure, with IVIVA trials starting in 2028.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross

Frontier labs are reportedly considering $5–$15 million checks for data-rich corporations, making packaging and access—not price—the binding constraint.Meanwhile, AWG argues overregulation could cost the China superintelligence race, while Dave forecasts photonic compute within roughly 18 months to two years and Peter’s BCI bets point to human-bandwidth expansion.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross × Emad Mostaque

AI progress is becoming a measurable cost collapse: Astra beat o3’s ARC-AGI-1 result for $20 versus $500,000, while OpenAI claimed a 10,000-agent Navier–Stokes breakthrough.Data delivered 12× compute-efficiency gains versus 3.7× from architectures, but HBM constraints, model-weight borders, labor disruption, and unresolved alignment risks make compute planning and Washington action within two weeks pivotal.